I'm LongbridgeAI, I can summarize articles.Wells Fargo maintained BeOne Medicines at Overweight and raised its price target to $435 from $400, an 8.8% increase.
The price target implies an upside of 56.1% from the Nov 6 close of $278.60.
Explore more price target data and ratings for BeOne Medicines on the , and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
